Abu Dhabi, United Arab Emirates, July 20, 2023: M42, an Abu Dhabi-based tech-
enabled healthcare company, signed a Memorandum of Cooperation (MoC) with
Japan’s National Institutes for Quantum Science and Technology (QST). The
agreement, inked during the visit of Japan's Prime Minister Fumio Kishida, aims to
share research around carbon ion therapy, an advanced form of radiation therapy
used to treat cancer.
The two bodies will leverage their combined experience to further their
understanding and knowledge of the technology. The collaboration is part of M42’s
commitment to delivering world-class patient-centric care enabled by advanced
technologies and innovative solutions.
Carbon ion therapy has gained significant interest globally due to advantageous
physical and radiobiologic properties compared to photon-based therapy. It allows
dose escalation to tumors while reducing radiation dose to adjacent normal tissues.
There are currently 16 centers around the world treating with carbon ion radiotherapy.
To date, it has been studied and proven effective for many types of malignancies.
QST is the world leader in carbon ion therapy since 1994.
Hasan Jasem Al Nowais, Group Chief Executive Officer and Managing Director of M42,
said: “We are honored to sign this MoC with QST, the leaders in charged particle radio
therapy, marking a pivotal milestone in our quest to expand clinical research in this
field. By working hand in hand, we are confident that our collaboration will enable
optimal cancer care, further potential clinical indications for carbon ion therapy, and
shape the future of healthcare in the region and beyond.”
Shigeo Koyasu, President of QST said: “It is wonderful to start research cooperation
with M42. This MOC will promote widespread use of carbon ion radiotherapy and help
build a healthy and long-lived society with zero cancer deaths.”
QST was established in 2016 and is striving to establish world-leading research and
development platforms, explore new fields, and serve as a center for radiation
protection and radiation emergency medicine.
M42 is an Abu Dhabi-based, global tech-enabled healthcare company operating at the
forefront of medical advancement. The company is seeking to transform lives through
innovative clinical solutions that can solve the world’s most critical health and diagnostic
challenges. By harnessing innovative solutions, unique medical and data-centric
technologies, including genomics and AI, M42 is transforming the traditional healthcare
ecosystem and delivering the highest level of precise, patient-centric, and preventative
M42 has over 20,000 employees and more than 450 facilities in 24 countries around the
world. Established in 2022, following the coming together of G42 Healthcare and Mubadala
Health, M42 is a first-of-its-kind integrated healthcare company that combines unique
medical and data-centric technologies with state-of-the-art facilities to deliver world-class
M42 owns a wide portfolio of assets that includes Amana Healthcare, Biogenix Labs, Danat Al
Emarat, Diaverum, HealthPoint Hospital, the HealthPlus network of specialty centers,
Moorfields Eye Hospital Abu Dhabi, Imperial College London Diabetes Centre, Insights
Research Organization & Solutions (IROS), Omics Center of Excellence and The National
Reference Laboratory, among others.
The National Institutes for Quantum Science and Technology (QST) was established in April
2016 to promote quantum science and technology in a comprehensive and integrated
QST’s mission is to raise the level of quantum and radiological sciences and technologies
through its commitment to research and development into quantum science and technology,
the effect of radiation on humans, radiation emergency medicine, and the medical use of
To ensure that research and development delivers significant academic, social and
economic impacts, and to maximize benefits from global innovation, QST is striving to
establish world-leading research and development platforms, explore new fields, and serve
as a center for radiation protection and radiation emergency medicine.